ASPIRIN ENTERIC SAFETY COATED
-
aspirin tablet, delayed release
Avema Pharma Solutions
Aspirin 81mg (NSAID)**
**nonsteroidal anti- inflammatory drug
Pain reliever
Reye’s syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not
use this product. When using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these
symptoms could be an early sign of Reye’s syndrome, a rare but serious illness.
Allergy alert: Aspirin may cause a severe allergic reaction which may include:
Stomach bleeding warning: This product contains a nonsteroidal anti-inflammatory drug (NSAID), which may cause stomach bleeding. The chance is higher if you:
you have high blood pressure, heart disease, liver cirrhosis, or kidney disease
you are taking a diuretic
you have asthma
taking a prescription drug for:
ask a health professional before use. It is especially important not to use aspirin during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
In case of overdose, get medical help or contact a Poison Control Center right away.
acetylated monoglycerides*, anhydrous lactose*, carnauba wax*, colloidal silicon dioxide,corn starch*, croscarmellose sodium*, D&C Yellow #10 Aluminum Lake, FD&C Yellow #6 Aluminum Lake, hypromellose, hypromellose phthalate*, iron oxide Yellow (iron
oxide ochre)*, methacrylic acid copolymer, microcrystalline cellulose, *mineral oil, polyethylene glycol (PEG)-400*, polysorbate 80*, povidone, pregelatinized starch, propylene glycol*, simethicone*, silicon dioxide, sodium bicarbonate, sodium hydroxide, sodium lauryl sulfate, starch, stearic acid, talc, titanium dioxide, triacitin, and triethyl citrate. *contains one or more of these ingredients
Call toll free 1-877-753-3935 Monday-Friday 9AM-5PM EST
Aspirin 81mg 300 count
ASPIRIN
ENTERIC SAFETY COATED aspirin tablet, delayed release | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
OTC MONOGRAPH FINAL | part343 | 08/11/2022 |
Labeler - Avema Pharma Solutions (804087794) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Avema Pharma Solutions | 804087794 | MANUFACTURE |